

## ERRATUM

# Correction to “Validation of 3- and 5-point severity scales to assess ARIA-E”

Bracoud L, Klein G, Lyons M, et al. Validation of 3- and 5-point severity scales to assess ARIA-E. *Alzheimer's Dement* (Amst). 2023;15:e12503.

In Table 1, the formatting of the cells was incorrect and suggested that amyloid-related imaging abnormality – edema (ARIA-E) with the greatest lesion extent being < 5 cm and with multiple regions affected, should be categorized as 1 (Mild) using the SSAE-3 scale; as opposed to being correctly categorized as 2 (Moderate). Please see the corrected Table 1 below.

**TABLE 1** Three-point and 5-point Severity Scales of ARIA-E.

ARIA-E extent	ARIA-E focality	SSAE-3	SSAE-5
No ARIA-E	N/A	0	0
<5 cm	Monofocal	1 (Mild)	1 (Mild)
<5 cm	Multifocal	2 (Moderate)	2 (Mild+)
5–10 cm	Monofocal	2 (Moderate)	3 (Moderate)
5–10 cm	Multifocal	2 (Moderate)	4 (Moderate+)
>10 cm	Monofocal	3 (Severe)	5 (Severe)
>10 cm	Multifocal	3 (Severe)	5 (Severe)

Abbreviations: ARIA-E, amyloid-related imaging abnormalities – edema; N/A, not applicable; SSAE, Severity Scale of ARIA-E.

We apologize for this error.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Authors. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.